MONTVALE, N.J., Sept. 21, 2007 (PRIME NEWSWIRE) -- Datascope Corp. (Nasdaq:DSCP) announced that its Board of Directors declared a regular quarterly cash dividend of $0.10 per share and a special dividend of $1.00 per share, payable October 15, 2007 to stockholders of record as of October 1, 2007.
The amount of the special dividend approximates the net proceeds received by the Company from the sale of the Company's investment in Masimo Corporation following that company's initial public offering in August 2007. The Board determined that it was appropriate to pass along to the stockholders the benefits of this transaction, as the Board believes that the Company's existing cash resources (after the special dividend), projected cash flows and unused credit lines are ample to meet the Company's needs.
About Datascope Corp.
Datascope Corp. is the global leader of intra-aortic balloon counterpulsation and a diversified medical device company that develops, manufactures and markets proprietary products for clinical health care markets in interventional cardiology and radiology, cardiovascular and vascular surgery, anesthesiology, emergency medicine and critical care. The Company has four product lines aggregated into two reporting segments, Cardiac Assist / Monitoring Products and Interventional / Vascular Products. The Company's products are sold throughout the world through direct sales representatives and independent distributors. Founded in 1964, Datascope is headquartered in Montvale, New Jersey. For news releases, webcasts and other Company information please visit Datascope's website, www.datascope.com.
The Datascope Corp. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3953
Safe Harbor Statement
This press release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Many of these risks cannot be predicted or quantified and are at least partly outside our control, particularly the risk that the special dividend may have an impact on the Company's ability to fund investment and growth, as well as other risks detailed in documents filed by Datascope with the Securities and Exchange Commission.